MiMedx Group, Inc. (NASDAQ:MDXG) Shares Bought by Fmr LLC

Fmr LLC lifted its position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 29.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,869 shares of the company’s stock after purchasing an additional 12,371 shares during the period. Fmr LLC’s holdings in MiMedx Group were worth $318,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. lifted its holdings in MiMedx Group by 909.0% in the 2nd quarter. Victory Capital Management Inc. now owns 138,449 shares of the company’s stock worth $959,000 after buying an additional 124,727 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of MiMedx Group by 88.6% during the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock worth $145,000 after acquiring an additional 11,557 shares during the last quarter. Isthmus Partners LLC increased its position in shares of MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after acquiring an additional 91,714 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after acquiring an additional 770,744 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in MiMedx Group by 47.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock valued at $8,958,000 after purchasing an additional 413,443 shares during the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $9.10 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The firm’s 50-day simple moving average is $8.01 and its 200-day simple moving average is $7.09. The firm has a market cap of $1.34 billion, a PE ratio of 16.55 and a beta of 1.98.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.